Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 18, 2026

Inside the Chaotic Iran Talks That Let Trump Claim Victory

View original at finance.yahoo.com
Inside the Chaotic Iran Talks That Let Trump Claim Victory (Bloomberg) -- It was fight night on the White House lawn. Beneath a great steel canopy nicknamed "the Claw," Justin Gaethje did a backflip off the caged ring in the center of the South Lawn after winning the Ultimate Fighting Championship title card…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Iranian negotiators warned that an Israeli strike on Beirut would blow up the talks.

    60% confidence

  • The Iran deal text had not been released at the time of announcement; the formal signing was still days away and the hardest questions — nuclear, sanctions, Lebanon — had been kicked down the road.

    60% confidence

  • The deal signing was delayed a few hours because of Israel's strikes on Beirut, and Trump called Netanyahu to berate him over it.

    60% confidence

  • The Deal with the Islamic Republic of Iran is now complete. I hereby fully authorize the toll free opening of the Strait of Hormuz, and, simultaneously herewith, authorize the immediate removal of the United States Naval blockade.

    60% confidence

  • The Israeli strike on Beirut should not have happened.

    60% confidence

  • Israel said it bombed southern Beirut in response to projectiles fired by Tehran-backed Hezbollah.

    60% confidence

Data points we hold from this source

Donald Trump · age80 years
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com